SAN DIEGO--(BUSINESS WIRE)--Ensysce Biosciences Inc. has been invited to attend conference Cutting Edge Science Meeting Series to End the Opioid Crisis: Development of Safe, Effective, Non-Addictive Pain Treatments taking place June 16, 2017 at the National Institutes of Health (NIH) Campus, Bethesda, MD. This conference is one of three that are planned to accelerate research to help end the opioid crisis in the major areas of (1) new and innovative medications/biologics to treat opioid addiction and for overdose prevention/reversal; (2) safe, effective, and non-addictive strategies to manage chronic pain; and (3) neurobiology of chronic pain. The NIH is bringing together some of the most creative and innovative experts from industry and academia to help identify the scientific strategies of greatest potential to expedite solutions for the opioid problem. The planned vigorous brainstorming sessions will provide opportunities to identify new approaches and recruit additional expertise to accelerate progress. Dr. William K. Schmidt, Chief Medical Officer of Ensysce will participate. Ensysce has been instrumental in developing highly novel opioid prodrug products that are unique in the industry. These BIO-MD™ abuse deterrent prodrugs are only effective if taken orally and activated through a two-step enzymatic process. The technology removes abuse by nasal or intravenous routes, and will not activate if chewed. The lead product in development, PF614 has recently completed a Phase 1 clinical study that demonstrated its safety and extended release pharmacokinetic profile with a 12 hour half-life, almost twice that of other marketed products. Additionally, Ensysce has addressed the problem of overdose abuse with its MPAR™ (Multi-Pill Abuse Resistance) Overdose Protection Technology that combines BIO-MD products with inhibitors that prevents activation when larger than prescribed doses are ingested.
About Ensysce Biosciences:
Ensysce Biosciences is an integrated drug delivery company for both small and large molecules. The BIO-MDTM and MPAR™ overdose resistant platforms eliminate the ability to abuse opioid products by the non-oral route, the fastest growing drug problem in the US leading to billions in healthcare costs annually. The technology, with a worldwide intellectual patent protection, has been successfully validated in Phase 1 studies of the BIO-MDTM hydromorphone prodrug, PF329 and oxycodone prodrug, PF614.